Researchers digging into why GLP-1 drugs like Ozempic and Wegovy don’t work for everyone just uncovered a surprising culprit: your genes. A new review published in Genome Medicine found that around 10% of people carry a genetic variation that makes these blockbuster medications far less effective. That’s not a small number—it’s about 33 million Americans who might struggle to lose weight or manage type 2 diabetes with these drugs alone. The study pulls together data from dozens of trials and genetic databases to show how specific tweaks in DNA can blunt the effects of GLP-1 receptor agonists, the class of drugs these medications belong to.

The discovery matters because GLP-1 drugs have become a go-to solution. Ozempic, originally approved for diabetes in 2017, and Wegovy, its higher-dose cousin for obesity in 2021, have been prescribed millions of times. They work by mimicking a hormone that curbs appetite and slows digestion. For many, they’re life-changing. But for the unlucky 10%, the results can feel underwhelming. The new review suggests these genetic roadblocks might explain why some people lose very little weight or see their blood sugar barely budge despite months of treatment. It’s not that the drugs are bad—it’s that their biology is working against them.

How your genes might sabotage your weight loss

The genetic snag is tied to a tiny change in the DNA sequence of a gene called TCF7L2. This gene helps regulate how your body produces and responds to insulin. In about one in ten people, a common variant flips a switch that weakens the body’s GLP-1 signal. Without a strong signal, the drug can’t do its job as well. The review authors say this variant is one of the most studied in diabetes research, but its role in GLP-1 drug resistance is just now getting clear attention.

Dr. Ruth Loos, a genetic epidemiologist at the Icahn School of Medicine at Mount Sinai who wasn’t involved in the study, called the findings “important but not surprising.” She pointed out that genetic differences have long shaped how people respond to medications. “We know statins don’t work the same for everyone, and the same goes for blood pressure drugs,” she said. “This is just another example of how genetics can dictate who benefits from a treatment—and who doesn’t.”

What to do if GLP-1 drugs aren’t working

If you’ve been taking Ozempic or Wegovy for months with little to show for it, the study offers a glimmer of hope. The authors suggest that switching to or adding different types of medications could break through the genetic wall. They point to combo therapies—like pairing a GLP-1 drug with a drug that targets a different pathway, such as bupropion-naltrexone or phentermine-topiramate. These pairings have shown promise in people who don’t respond to GLP-1 drugs alone.

Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital, said personalized treatment plans are the future. “We’re moving away from one-size-fits-all approaches,” she said. “If GLP-1s aren’t cutting it, we can look at your genetics, your medical history, and your lifestyle to find a better fit.” She added that lifestyle changes—like structured meal timing, resistance training, and sleep optimization—can also complement medication in ways that might bypass genetic roadblocks.

The bigger picture: How genetics is reshaping obesity care

This isn’t just about GLP-1 drugs. The review highlights a growing trend in medicine: using genetic testing to tailor treatments. Companies like 23andMe and Nebula Genomics already sell reports that hint at how you might respond to certain drugs. While these aren’t medical-grade yet, they’re a sign of where things are headed. The goal is to move beyond trial-and-error prescribing and into precision medicine.

But there’s a catch. Genetic testing isn’t cheap, and insurance doesn’t always cover it for weight loss or diabetes management. Plus, not everyone has easy access to a doctor who specializes in obesity medicine. For now, experts say the best approach is to talk to your doctor about your response to GLP-1 drugs. If you’re not seeing results, ask about alternative strategies—not just another prescription, but a whole plan that fits your biology.

The road ahead

Researchers are already working on next steps. Larger trials are needed to confirm which genetic markers predict GLP-1 drug resistance most reliably. They’re also testing whether adjusting doses or combining drugs can overcome these barriers. In the meantime, the message is clear: GLP-1 drugs aren’t magic pills for everyone. If they’re not working for you, it’s not your fault—and there are other paths to try.

What You Need to Know

  • Source: Healthline
  • Published: May 16, 2026 at 22:55 UTC
  • Category: Health
  • Topics: #health · #wellness · #medicine · #science · #biology · #genetics

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on Healthline →

All reporting rights belong to the respective author(s) at Healthline. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 16, 2026

🇧🇷 Resumo em Português

Uma em cada dez pessoas no Brasil pode não responder aos medicamentos para emagrecimento baseados em GLP-1, como o Ozempic, devido a uma variação genética que impede sua eficácia. Essa descoberta, revelada por um estudo recente, joga luz sobre um problema que afeta milhões de brasileiros que buscam alternativas para controlar o peso e a diabetes, mas esbarram em soluções que não funcionam da mesma forma para todos.

O GLP-1 é um hormônio produzido naturalmente pelo intestino que regula o apetite e a glicose no sangue, e medicamentos como o Ozempic e o Wegovy foram desenvolvidos para imitar sua ação. No entanto, pesquisadores identificaram que cerca de 10% da população possui uma mutação genética que reduz a capacidade dessas drogas de se ligarem aos receptores do intestino, diminuindo seu efeito. No Brasil, onde o mercado de medicamentos para emagrecimento movimenta bilhões de reais e a obesidade atinge mais de 20% da população adulta, essa descoberta é especialmente relevante. Ela reforça a necessidade de abordagens personalizadas no tratamento da obesidade e da diabetes, que vão além das soluções farmacológicas padronizadas e incluem mudanças no estilo de vida e, possivelmente, terapias genéticas no futuro.

A próxima fronteira da medicina pode estar justamente na identificação prévia de quem responde ou não a esses medicamentos, permitindo que médicos e pacientes optem por alternativas mais eficazes desde o início.

🇪🇸 Resumen en Español

Un estudio reciente ha revelado por qué los fármacos como Ozempic, basados en el péptido similar al glucagón tipo 1 (GLP-1), no surten efecto en cerca del 10% de las personas que los consumen, abriendo un nuevo frente en la batalla contra la obesidad y la diabetes.

La investigación, publicada en la revista Nature Medicine, ha identificado que una variante genética específica —presente en aproximadamente uno de cada diez pacientes— bloquea la acción de estos medicamentos al interferir con su mecanismo de acción. Esto significa que, mientras la mayoría de los usuarios experimentan una reducción significativa del apetito y mejoras en el control glucémico gracias a la activación de los receptores de GLP-1, quienes portan esta mutación genética no obtienen los mismos beneficios. Para ellos, los expertos sugieren explorar alternativas como combinaciones de fármacos, cambios en el estilo de vida más intensivos o incluso intervenciones quirúrgicas, como el bypass gástrico, que han demostrado ser eficaces en casos resistentes. El hallazgo subraya la importancia de la medicina personalizada en el tratamiento de enfermedades metabólicas, donde la genética puede ser la clave para decidir qué terapia es más adecuada.